Search
Vor Biopharma Inc
VORAdd to Watchlist
20.590USD
+2.200+11.96%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
185.86MMarket Cap
LossP/E TTM
More Details of Vor Biopharma Inc Company
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
Vor Biopharma Inc Info
Ticker SymbolVOR
Company nameVor Biopharma Inc
IPO dateFeb 05, 2021
CEOKress (Jean-Paul)
Number of employees159
Security typeOrdinary Share
Fiscal year-endFeb 05
Address500 Boylston Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02116
Phone16176556580
Websitehttps://www.vorbio.com/
Ticker SymbolVOR
IPO dateFeb 05, 2021
CEOKress (Jean-Paul)
Company Executives of Vor Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
1.00
-69413700.00%
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
--
--
Mr. Dallan Murray
Mr. Dallan Murray
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Sarah Reed
Ms. Sarah Reed
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
1.00
-69413700.00%
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
--
--
FAQs
Who are the top five shareholders of Vor Biopharma Inc?
The top five shareholders of Vor Biopharma Inc are: Mr. Sandesh (Sandy) Mahatme
How many institutions hold shares of Vor Biopharma Inc (VOR)?
As of 2026Q1, 192 institutions hold shares of Vor Biopharma Inc, with a combined market value of approximately 33.33M, accounting for 62.59% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 23594097.00.